Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Labcorp (NYSE:LH) Stock in a Busy Session: Third Quarter 2026 Results, Raised Full-Year Guidance and Acquisition Agreements

Labcorp Holdings Inc. (NYSE:LH) shares were trading at USD 363.94 on October 28, 2026, up 9.90%, with a relative volume at time of 3.51. The laboratory services company announced a quarterly dividend on October 21, signed three acquisition agreements after quarter end and reported …

Nitish Kishor | 28 October 2026

Penumbra (NYSE:PEN) Stock Actively Traded Today: Second Quarter 2026 Results, Boston Scientific Merger Agreement and Liquidity

Penumbra (NYSE:PEN) shares were trading at USD 320.08 on October 28, 2026, down 1.22%, with a relative volume at time of 3.01. The thrombectomy company has a pending merger agreement with Boston Scientific Corporation dated January 14, 2026 and filed its Form 10-Q for …

Nitish Kishor | 28 October 2026

ACADIA Pharmaceuticals (NASDAQ:ACAD) Undervalued Growth Stock Review: Second Quarter Earnings, Product Sales and Pipeline Milestones

Basic earnings per share growth of 66.40% over one year, a trailing twelve-month P/E of 8.94 and a PEG of -0.08 on an expected basis define ACADIA Pharmaceuticals (NASDAQ:ACAD) as an undervalued growth stock, with shares trading at USD 20.32 on October 28, 2026, …

Nitish Kishor | 28 October 2026

Aveanna Healthcare (NASDAQ:AVAH) Undervalued Growth Stock Review: Second Quarter 2026 Earnings, Family First Acquisition and Raised Guidance

One-year earnings growth of 1,199.54% in basic earnings per share, paired with a trailing twelve-month P/E ratio of 10.85 and a PEG ratio of -31.81 on an expected basis, puts Aveanna Healthcare (NASDAQ:AVAH) among undervalued growth stocks, with shares trading at USD 13.03 on …

Nitish Kishor | 28 October 2026

A Closer Look at Bristol-Myers Squibb (NYSE:BMY): Undervalued Growth Stock, Second Quarter 2026 Earnings, Eliquis and 2026 Guidance in Focus

Bristol-Myers Squibb (NYSE:BMY) reported second quarter 2026 net earnings attributable to BMS of $3,317 million, and the undervalued growth stock figures read 82.74% one-year growth in basic earnings per share, a trailing twelve-month P/E of 13.53 and an expected-basis PEG of -16.94, with shares …

Nitish Kishor | 28 October 2026

Indivior (NASDAQ:INDV) Undervalued Growth Stock Review: Second Quarter Earnings, Supernus Merger and Share Repurchases

Basic earnings per share growth of 227.70% over one year, a trailing twelve-month P/E of 12.46 and a PEG of 0.00 on an expected basis define Indivior (NASDAQ:INDV) as an undervalued growth stock, with shares trading at USD 34.35 on October 28, 2026, down …

Nitish Kishor | 28 October 2026

Abbott Laboratories (NYSE:ABT) Narrows Full-Year Guidance as Legal Charges Weigh on Reported Earnings

● Adjusted diluted earnings were $1.42 per share, while reported earnings fell to 53 cents.

Nitish Kishor | 28 October 2026

German Medical Demand Grows at Aurora Cannabis (NASDAQ:ACB) as Canadian Reimbursement Cuts Bite

● International medical revenue rose about 17% to roughly 43 million Canadian dollars on German demand.

Nitish Kishor | 28 October 2026

Amgen (NASDAQ:AMGN) Hosts an ESMO Oncology Webcast While Raised Guidance and MariTide Stay in View

● Second quarter revenue exceeded $10 billion, up 10%, and full-year guidance was raised.

Nitish Kishor | 28 October 2026

Arcturus Therapeutics (NASDAQ:ARCT) Bets on Cystic Fibrosis After the CSL Seqirus Exit

● Cash was $191.5 million at June 30, with runway management puts through 2028.

Nitish Kishor | 28 October 2026
Support

Hi! How can we help you today?

Loading…